Boryeong Holdings establishes a US subsidiary

Started a corporation in San Francisco, USA on the 22nd of last month

BR2002 Development Project is expected to accelerate

Boryeong Holdings announced on January 22 that it established a local corporation in San Francisco, USA and officially started business.

 

The local corporation name is ‘HAYAN HEALTH NETWORKS’, and Sung-won Choi, currently the executive director of the global business headquarters of Boryung Pharmaceutical, will be the first director.

 

Boryeong Holdings explained that it had established a base in San Francisco called Hub of Bio and Life Sciences Venture Investment in the Western United States to network and accumulate information with global pharmaceutical companies, investors and early stage R & D companies in the US and Europe.

 

The company is also planning to strengthen strategic alliances and cooperation with business companies such as Boryeong Pharmaceutical, Boryeong Bio Pharma, and Boryeong Consumer.

 

Boryeong pharmaceutical, a subsidiary of Boryeong Holdings, is expected to accelerate the development of the next-generation target cancer drug 'BR2002'.

 

BR2002 is a new drug candidate material that Boryung Pharmaceutical received from Korea Chemical Research Institute in 2016.

 

It represents a mechanism that simultaneously inhibits PI3Kδ (phosphoinositide-3 kinase delta) and DNA-PK (oxyribonucleotide protein kinase), which are the major growth and regulatory factors of cancer cells.

 

Boryung Pharm has proposed the goal of promoting global technology exports while simultaneously conducting clinical trials of 'BR101801' in Korea and the United States.

 

Sung-Won Choi, the first director of the company, said, “The competitiveness of the biohealth care industry, where the borders of AI and digital disappear and speed becomes important, is information and networks.

 

We will increase investment efficiency and strengthen R & D cooperation by opening a local subsidiary in the United States, which is the world's largest pharmaceutical market and has infrastructure including universities, research institutes, experts and capital”.